Skip to main content
Menu

Posts tagged with "The Dark Side"

  • Current Events

    The Politics of Hydroxychloroquine

    I had not been planning to return to the topic of hydroxychloroquine so soon, but here we are. This will not be a calm, measured blog post – fair warning. Yesterday, Dr. Rick Bright was pushed out of his post at HHS, where he was deputy assistant secretary for preparedness and response and director of BARDA… Read More
  • Current Events

    Harvard’s Chemistry Dept. Chairman in FBI Custody

    I suspect that most readers will have heard the news that Charles Lieber, nanoscale materials chemist and chair of Harvard’s chemistry department, was arrested yesterday by federal agents. He was accused of providing false statements to government agencies about his involvement with China’s “Thousand Talents” program and wit… Read More
  • The Dark Side

    A Very Public Retraction. Good.

    Word came out yesterday from Frances Arnold of Caltech (via her Twitter account) that she and her co-authors are retracting this paper from Science. The retraction notice itself has the details: After publication of the Report “Site-selective enzymatic C‒H amidation for synthesis of diverse lactams” (1), efforts to reproduce the work showed t… Read More
  • Academia (vs. Industry)

    The Hype Problem

    This paper is right, and it says things that need to be said. I wonder, though, if saying them will do any good. Let me explain what the heck I’m talking about! The paper is titled “Blocking the Hype-Hypocrisy-Falsification-Fakery Pathway is Needed to Safeguard Science“, and I don’t see how anyone can really disagree. When… Read More
  • Snake Oil

    A Research Scandal in China

    This is not going to be a reassuring story – not for the biomedical literature, and not for the Chinese scientific establishment. But the head of the official Research Integrity initiative there, Xuetao Cao, a former head of the Chinese Academy of Medical Sciences and current president of Nankai University, is now thoroughly involved in… Read More
  • The Dark Side

    Cite My Papers. Or Else.

    The ways to mess around with the peer-review process are legion, but these schemes are getting a bit easier to catch. That’s what I take away from this paper, from two bibliographic scientists at Elsevier who set up a system to do just that. One hears tales of reviewers who will look more favorably on… Read More
  • Regulatory Affairs

    Tales From FDA Site Inspections

    It’s a summer Friday, so I’ll just send along this link to a story at Wired. It’s similar to this recent post, in that it details some of the ridiculous ways that small overseas manufacturers have tried to get around FDA site inspections. As a correspondent noted, though, the title of the Wired article isn’t… Read More
  • Clinical Trials

    An Awful Idea: Paying to Get Into a Clinical Trial

    This article at Stat by Rebecca Robbins really caught me eye. It describes clinical trials where the participants are being asked to pay thousands of dollars just to join the trial. There seems to have been an increase in this sort of thing lately, and I’ll be completely clear: I think that’s a terrible idea… Read More
  • Snake Oil

    The Bottom of the Stem Cell Barrel

    In case anyone was wondering, the commercial stem cell clinic business is still shady and full of hype, profiteering, and outright fraud. Overflowing with all of those, actually. And although there are people turning profits on this stuff all over the country, it may not surprise to learn that there’s an awful lot of it… Read More
  • Academia (vs. Industry)

    Researching While Chinese

    One of my basic principles is that “Just because you can mess things up by going in one direction doesn’t mean that you can’t mess them up by doing the opposite”. And we may be proving that one again, with this example being the position of Chinese researchers in the US. I will stipulate up… Read More
123...